ATE72399T1 - Von saeure gespaltete verbindung. - Google Patents

Von saeure gespaltete verbindung.

Info

Publication number
ATE72399T1
ATE72399T1 AT85902881T AT85902881T ATE72399T1 AT E72399 T1 ATE72399 T1 AT E72399T1 AT 85902881 T AT85902881 T AT 85902881T AT 85902881 T AT85902881 T AT 85902881T AT E72399 T1 ATE72399 T1 AT E72399T1
Authority
AT
Austria
Prior art keywords
cross
linkers
disclosed
active substance
acid
Prior art date
Application number
AT85902881T
Other languages
English (en)
Inventor
Walter A Blattler
John M Lambert
Peter D Senter
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE72399T1 publication Critical patent/ATE72399T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT85902881T 1984-08-29 1985-05-23 Von saeure gespaltete verbindung. ATE72399T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/645,614 US4542225A (en) 1984-08-29 1984-08-29 Acid-cleavable compound
PCT/US1985/000980 WO1986001409A1 (en) 1984-08-29 1985-05-23 Acid-cleavable compound
EP85902881A EP0191772B1 (de) 1984-08-29 1985-05-23 Von säure gespaltete verbindung

Publications (1)

Publication Number Publication Date
ATE72399T1 true ATE72399T1 (de) 1992-02-15

Family

ID=24589735

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90202465T ATE135003T1 (de) 1984-08-29 1985-05-23 Durch säuren spaltbare verbindungen
AT85902881T ATE72399T1 (de) 1984-08-29 1985-05-23 Von saeure gespaltete verbindung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90202465T ATE135003T1 (de) 1984-08-29 1985-05-23 Durch säuren spaltbare verbindungen

Country Status (7)

Country Link
US (3) US4542225A (de)
EP (2) EP0191772B1 (de)
JP (2) JPH06102679B2 (de)
AT (2) ATE135003T1 (de)
CA (1) CA1241949A (de)
DE (2) DE3585369D1 (de)
WO (1) WO1986001409A1 (de)

Families Citing this family (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5144011A (en) * 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
US4889916A (en) * 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5017693A (en) * 1987-12-02 1991-05-21 Neorx Corporation Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
US5141648A (en) * 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
DE3873887T2 (de) * 1987-12-02 1993-02-04 Neorx Corp Spaltbare immun-conjugate fuer die abgabe und freisetzung von agenzien in natuerlicher form.
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
WO1990014844A2 (en) * 1989-06-06 1990-12-13 Neorx Corporation Sugars as cleavable linkers for the delivery and release of agents in native form
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
US5874549A (en) * 1990-09-28 1999-02-23 Neorx Corporation Acid-cleavable compound
FI101678B (fi) * 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5242680A (en) * 1991-08-23 1993-09-07 Merck & Co., Inc. Thiol-reactive maleimido-based radiolabeling reagents
US5679777A (en) * 1991-11-08 1997-10-21 Somatogen, Inc. Hemoglobins as drug delivery agents
WO1993013768A1 (en) * 1992-01-06 1993-07-22 Ariad Pharmaceuticals, Inc. Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5612474A (en) * 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5830478A (en) * 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US8217015B2 (en) * 2003-04-04 2012-07-10 Arrowhead Madison Inc. Endosomolytic polymers
EP0871490B1 (de) * 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Verzweigte hydrazongruppen enthaltende kuppler
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6960457B1 (en) * 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
AU1539699A (en) 1997-11-24 1999-06-15 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
EP1792988A3 (de) 1998-03-18 2007-08-22 Corixa Corporation Verbindungen und Verfahren für Therapie und Diagnose von Lungenkrebs
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
ATE399793T1 (de) 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
US20040146516A1 (en) * 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
AU2001227679A1 (en) * 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001071352A2 (en) * 2000-03-17 2001-09-27 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
DE60137953D1 (de) 2000-10-06 2009-04-23 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
AU2002230524A1 (en) * 2000-11-16 2002-05-27 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP4342934B2 (ja) * 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Ｐｅｐｔ−２輸送体を介した薬剤の投与
EP1463796B1 (de) 2001-11-30 2013-01-09 Fluidigm Corporation Mikrofluidische vorrichtung und verfahren zu ihrer verwendung
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
WO2003076651A2 (en) * 2002-03-14 2003-09-18 Qlt Inc. Cancer associated araf1 protein kinase and its uses
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
US7211250B2 (en) 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1852441B1 (de) 2002-09-24 2012-03-28 The Burnham Institute Mittel zur Modulierung der EPH-Rezeptor-Aktivität
AU2003275449A1 (en) * 2002-10-07 2004-05-04 Wei Liu Compositions, organisms and methodologies employing a novel human kinase
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
US7122361B2 (en) * 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
EP1549749A4 (de) * 2002-10-10 2007-08-22 Wyeth Corp Zusammensetzungen, organismen und methoden unter verwendung einer neuen humanen kinase
WO2004036221A2 (en) * 2002-10-18 2004-04-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
CA2503491A1 (en) * 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
WO2004050831A2 (en) 2002-11-27 2004-06-17 Wyeth Compositions, organisms and methodologies employing a novel human kinase
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
JP2007537984A (ja) * 2003-03-04 2007-12-27 ワイス 喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
EP1615721B1 (de) 2003-04-03 2014-06-18 Fluidigm Corporation Mikrofluidvorrichtungen und verwendungsverfahren dafür
EP1618199A2 (de) * 2003-04-10 2006-01-25 Aristex Affinitätsreinigungsverfahren durch troponinmoleküle als affinitätsliganden
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
EP1498445A1 (de) * 2003-07-18 2005-01-19 DSM IP Assets B.V. Wärmestabilisierte Formmasse
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP1720569B1 (de) * 2004-02-27 2014-10-29 Immune System Therapeutics Ltd Target für b-zell-störungen
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
EP1771205B1 (de) 2004-06-18 2016-10-26 Ambrx, Inc. Neuartige antigen-bindende polypeptide und ihre verwendungen
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
EP1828405A4 (de) * 2004-11-16 2009-04-15 Sienna Cancer Diagnostics Ltd Verfahren zum nachweis eines analyten in einer probe
BRPI0519170A8 (pt) * 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
JP4990792B2 (ja) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
EP1861512A4 (de) 2005-03-18 2009-12-09 Fluidigm Corp Wärmereaktionsvorrichtung und verwendungsverfahren dafür
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
WO2007021297A1 (en) * 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
WO2007051077A2 (en) * 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
CU23544A1 (es) * 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
US8524454B2 (en) * 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP1864682A1 (de) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycinderivate
AU2007292892B9 (en) * 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
KR20090060294A (ko) * 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
KR20090091145A (ko) * 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
JP5650406B2 (ja) 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101675071B (zh) * 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
AU2008302345A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2009039584A1 (en) 2007-09-28 2009-04-02 Welcome Receptor Antibodies Pty Ltd Diagnosis and treatment of diseased and damaged tissue
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2297178B1 (de) * 2008-05-27 2014-07-30 Genzyme Corporation Peptidanaloga des alpha-melanozytstimulierenden hormons
EP2310498A1 (de) 2008-06-26 2011-04-20 Atyr Pharma, Inc. Glycyl-trna-synthetasen mit nichtkanonischen biologischen aktivitäten umfassende zusammensetzungen und verfahren
CA2729403A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
NZ623273A (en) 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
CN102438580B (zh) 2009-02-06 2015-06-17 加利福尼亚大学董事会 钙结合剂诱导毛发生长和/或甲生长
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法
WO2010120509A2 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
ES2535951T3 (es) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidil ARNt sintetasas para reducir la inflamación
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
BR112013007069A2 (pt) 2010-09-29 2016-09-13 Uti Limited Partnership métodos para tratar doença autoimune usando nanoesferas biocompatíveis e bioabsorvíveis
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US8609818B2 (en) 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US20140170068A1 (en) 2011-03-11 2014-06-19 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
JP2014527398A (ja) 2011-06-21 2014-10-16 オンコファクター コーポレイション がんの療法および診断のための組成物および方法
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
EP3536700A1 (de) 2012-06-07 2019-09-11 Ambrx, Inc. Antikörper-wirkstoff-konjugate für prostataspezifisches membranantigen
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US10188693B2 (en) 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
AU2014252666B2 (en) 2013-04-08 2017-02-02 Helix Biopharma Corp. Use of antibody-urease conjugates for diagnostic and therapeutic purposes
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3139965B1 (de) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Von cholixtoxin abgeleitete fusionsmoleküle zur oralen verabreichung von biologisch aktiven stoffen
WO2015183988A1 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including therapeutic small molecules and uses thereof
US10576124B2 (en) 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
WO2016072938A1 (en) 2014-11-05 2016-05-12 Nanyang Technological University Stabilized and autonomous antibody vh domain
WO2016141230A1 (en) 2015-03-05 2016-09-09 Sirenas Llc Cyclic peptide analogs and conjugates thereof
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
CN108348603B (zh) 2015-11-03 2023-12-29 Ambrx公司 抗cd3叶酸结合物和其用途
EP3383920B1 (de) 2015-11-30 2024-01-10 The Regents of the University of California Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2018045245A1 (en) 2016-09-02 2018-03-08 Sirenas Llc Cyclic peptide analogs and conjugates thereof
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
WO2018111782A1 (en) 2016-12-12 2018-06-21 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
MA50265A (fr) 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
EP3716949A4 (de) 2017-11-29 2022-05-18 UTI Limited Partnership Verfahren zur behandlung von autoimmunerkrankungen
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
CA3093386A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202009670RA (en) 2018-03-29 2020-10-29 Ambrx Inc Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
EP3844188A1 (de) 2018-08-28 2021-07-07 Ambrx, Inc. Anti-cd3-antikörper-folat-biokonjugate und ihre verwendungen
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
WO2020081174A1 (en) 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3980423A1 (de) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidin-2,4-diaminverbindungen und ihre antikörper-konjugate
EP3983410A1 (de) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-aminderivate und verwandte verbindungen als toll-like- rezeptor (tlr) 7/8-agonisten sowie antikörper-wirkstoff-konjugate davon zur verwendung in der krebstherapie und -diagnose
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4117732A1 (de) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und verfahren zur verwendung davon
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US12428457B2 (en) 2021-01-29 2025-09-30 University Of South Florida Cold-shock protein scaffold for engineering non-antibody binding proteins
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN117396231A (zh) 2021-04-30 2024-01-12 新基公司 使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
IL317782A (en) 2022-06-30 2025-02-01 Sutro Biopharma Inc Anti-ROR1 antibodies and conjugates thereof, compositions containing anti-ROR1 antibodies or conjugates thereof, and methods for preparing and using anti-ROR1 antibodies and conjugates thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
US20260103629A1 (en) 2022-09-20 2026-04-16 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
KR20250137203A (ko) 2022-12-27 2025-09-17 예일 유니버시티 항체 약물 접합체
JP2026504093A (ja) 2023-01-16 2026-02-03 アンブレツクス・インコーポレイテツド 抗ｃｄ７０抗体薬物コンジュゲート
EP4655007A1 (de) 2023-01-23 2025-12-03 Yale University Antikörper-oligonukleotid-konjugate
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
EP4766404A1 (de) 2023-08-22 2026-07-01 Ambrx, Inc. Anti-psma-adc-konjugatzusammensetzungen und verfahren zur verwendung davon
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
EP4791439A1 (de) 2023-10-13 2026-08-19 Sutro Biopharma, Inc. Antikörper-wirkstoff-konjugate mit doppelter nutzlast
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2026020051A1 (en) 2024-07-19 2026-01-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading aurora kinase via ubiquitin proteosome pathway
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026080688A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Dual mechanism of action payload antibody drug conjugates
WO2026080697A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
WO2026165269A1 (en) 2025-01-29 2026-08-06 Sutro Biopharma, Inc. Anti-b7-h3 antibodies, compositions comprising anti-b7-h3 antibodies and methods of making and using anti- b7-h3 antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2197574A (en) * 1937-09-23 1940-04-16 Wingfoot Corp Vulcanization of rubber
US3455832A (en) * 1963-09-09 1969-07-15 Monsanto Co Schiff bases
US4107174A (en) * 1975-06-18 1978-08-15 Ciba-Geigy Corporation Imidyl compounds
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4410542A (en) * 1978-12-30 1983-10-18 Santen Pharmaceutical Co., Ltd. Disulfide compounds
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
JPS5764617A (en) * 1980-10-08 1982-04-19 Teijin Ltd Cytotoxic proteinic complex and its preparation
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法

Also Published As

Publication number Publication date
US4569789A (en) 1986-02-11
JPH0684372B2 (ja) 1994-10-26
US4618492A (en) 1986-10-21
JPH06102679B2 (ja) 1994-12-14
CA1241949A (en) 1988-09-13
DE3588090T2 (de) 1996-07-18
EP0191772A4 (de) 1988-11-09
ATE135003T1 (de) 1996-03-15
EP0191772A1 (de) 1986-08-27
EP0191772B1 (de) 1992-02-05
EP0408157B1 (de) 1996-03-06
EP0408157A1 (de) 1991-01-16
DE3585369D1 (de) 1992-03-19
DE3588090D1 (de) 1996-04-11
JPS62500100A (ja) 1987-01-16
WO1986001409A1 (en) 1986-03-13
JPH04356483A (ja) 1992-12-10
US4542225A (en) 1985-09-17

Similar Documents

Publication Publication Date Title
DE3585369D1 (de) Von saeure gespaltete verbindung.
KR900700591A (ko) 세포 혼합물로부터 특정 세포를 분리하는 다단계 친화방법
FI854363A0 (fi) Prefabricerade moduler och anvaendning av dem i byggnadsindustrin.
DE3874498D1 (de) Kombinationen elektrochemischer zellen von laenglicher form.
ATE234637T1 (de) Verbesserungen von oder in bezug auf endometrialfunktion
TR22204A (tr) Yeni 1-0-tritilgliserofosfokolin veya(1-0,n-ditritil)-gliserofosfoetanolamin bilesikleri vasitasiyle c1 ve c2 uezerinde farkh olarak suebstituee edilmis olan fosfatidikolinlerin ve fosfatidil etanolamin'lerin imal edilmesine mahsus usul
DE3863095D1 (de) Korrosionsbestaendige brennstoffzellenstruktur.
DK543087A (da) Fremgangsmaade til fremstilling af 2,6-di-tert.butyl-4-mercaptophenol samt fremgangsmaade til fremstilling af derved anvendeligt mellemprodukt
SE8405431L (sv) Amfipatisk gelprodukt for kromatografisk och satsvis adsorption
DE3775389D1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
DK306285A (da) Organolermaterialer
DE3773077D1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3771668D1 (de) Aktivierbare zelle.
NO872420D0 (no) Elektrokjemisk cellesammensetning.
FI853324A0 (fi) Nytt mekaniskt behandlingsfoerfarande foer isolering av bakterieceller fraon rekombinat framstaellda peptider.
ATE68601T1 (de) Reagenz zur bestimmung durch haemagglutination von antikoerpern gegen bakterien-toxine, verfahren zu ihrer herstellung und verwendung.
DE3583245D1 (de) Herstellung von aminosaeuren durch biologischen austausch.
DE3485981D1 (de) Biosynthetische 2,5-diketoglukonsaeure-reduktase, verfahren, rekombinante zellen und expressionsvektoren zu deren herstellung und ihre verwendung zur herstellung von 2-keto-l-gulonsaeure.
JPS57193494A (en) Method of purifying or concentrating biologically active protein and drug therefor
DK436685D0 (da) Fremgangsmaade til fremstilling af 2,4-dichlor-5-fluor-benzoesyre
IL44878A (en) Process for separating ionized substances from their aqueous solutions
BE882785A (fr) Electrolyte acide contenant de l'etain bivalent
AT388933B (de) Verfahren zur herstellung von biokatalysatoren durch immobilisierung von enzymatisch aktivem zellmaterial
DE3575718D1 (de) Bromodichlorimidazolderivate als insektizide.
AT379393B (de) Verfahren zur herstellung neuer 6-hydrazono-pyrido(2,1-b)chinazolin-11-on-deriv te, von deren salzen sowie von deren stereomeren